SAN DIEGO , Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 100,000 samples received to date for processing
SAN DIEGO, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today provided a business update following the recent filing with the US Securities
Announces distribution of approximately 83,000 specimen collection kits to clients SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
Announces distribution of approximately 46,000 specimen collection kits to clients SAN DIEGO , Aug. 31, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
Announces receipt of more than 150,000 samples for COVID-19 testing and completes relocation to new facility SAN DIEGO , Dec. 14, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians
Results demonstrate high level of analytical sensitivity and specificity for the Company's non-invasive, clinically actionable biomarker test for immunotherapy
Ability to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2022-- Biocept, Inc .
Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)
Expands intellectual property position to 26 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers found in tissue, blood and other biological sources SAN DIEGO , March 29, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
Expands intellectual property to 30 issued patents globally for highly sensitive methods of detecting cancer biomarkers SAN DIEGO , Oct. 18, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
